POT-4 is a complement inhibitor, which shuts down the complement activation system that could lead to local inflammation, tissue damage and upregulation of angiogenic factors such as vascular endothelial growth factor.
Four landmark studies published in April 2005 demonstrated a genetic link between the complement system and AMD, providing evidence that complement activation plays a significant role in the cause of the disease. POT-4 will be the first complement inhibitor tested in patients with AMD.
“These recent data have sparked hope that AMD can be treated with complement inhibitors, which help treat the early stages of the disease. We are hopeful that POT-4 may represent a new therapeutic option for patients with dry and wet forms of the disease,” said Cedric Francois, Potentia's president and CEO.
AMD is the progressive deterioration of the critical central region of the retina called the macula. This disorder leads to irreversible loss of central vision. More than 25 million patients worldwide suffer from AMD, including roughly one-quarter of those 70 years and older.